Cardiac Insight

Cardiac Insight is a U.S.-based medical device innovator focused on cardiac diagnostics and digital health. Its core products are the FDA-cleared Cardea SOLO, a 7-day wearable ambulatory ECG sensor with rapid in-office analysis software, and the Cardea 20/20, a handheld 12-lead ECG device for athletic screening. Founded in 2010, the company differentiates itself through a physician-centric data ownership model and fast report turnaround. A 2021 partnership with DreamTech positions it for growth in the competitive cardiac monitoring market.

Proprietary hardware and software platform for ECG acquisition and analysis, featuring the Cardea SOLO (7-day wearable ambulatory monitor) and Cardea 20/20 (handheld 12-lead ECG), with an emphasis on algorithm-driven interpretation, data ownership by the physician, and rapid in-office reporting.

Cardiac Insight competes directly with major players like iRhythm (Zio), Philips, and Boston Scientific in ambulatory monitoring. Its key differentiation is the physician-owned data model and rapid in-office software analysis, contrasting with the outsourced diagnostic service model used by many competitors, as highlighted in its detailed competitor chart.